NSCLC (following checkpoint inhibitors; combo with docetaxel) | XPORT-NSCLC-039

Indication: NSCLC
Title: Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT)
Drug: Selinexor

Please visit clinicaltrials.gov for more information about this study

This trial is for selinexor.